Grants for For profit organizations other than small businesses - Federal

This funding opportunity supports innovative research aimed at preventing Alzheimer’s disease and related dementias, particularly in relation to military service and traumatic brain injury, targeting independent researchers from various eligible organizations.

This initiative seeks input from various stakeholders, including businesses, researchers, and government entities, to enhance the recycling and reuse of products and materials, ultimately promoting environmental sustainability and economic resilience.

The U.S. National Science Foundations Directorate for Technology, Innovation and Partnerships (TIP) is charged with accelerating use-inspiredand translationalresearch and development (R) to advance U.S. competitiveness in key technology focus areas. The Advancing Cell-Free Systems Toward Increased Range of Use-Inspired Applications (CFIRE) initiative will accelerate the adoption of cell-free systems, enable new applications of this technology and contribute to the growth of the U.S. bioeconomy. A nascent industry has formed around the ability to carry out biochemical processes, such as DNA transcription/translation, in cell-free in-vitro systems instead of in traditional cell-based in-vivo bio-reactors. This approach has a number of potential advantages, including rapid turn-around, distributed and highly retargetable manufacturing, high-fidelity instrumentation and control of the manufacturing environments without the constraints of biological growth and the interference caused by cell biomass and cell membranes during product purification. Furthermore, cell-free systems can produce products that are challenging to manufacture in cell-based cultures, such as those inherently toxic to cells or hydrocarbon products that are consumed by the cellular machinery. Despite these advantages, present-day cell-free manufacturing is significantly more expensive than cell-based methods and cell-free systems have a limited range of applications. CFIRE aims to: 1. Reduce the cost of cell-free systems; 2. Increase the range and capabilities of cell-free systems; and 3. Develop and demonstrate cost-effective use-inspired applications. CFIRE will address the key limitations of cell-free technology by identifying technical approaches that can enable ongoing cycles of improvement. The objective is to place cell-free technology on an exponential growth path in which reduced costs lead to increasing adoption which, in turn, generates the learning and investment required to further reduce costs. In order to keep the work focused and to stimulate increasing adoption, efforts funded through this initiative will focus on one or more specific use cases. CFIRE seeks significant breakthroughs that will accelerate the adoption of cell-free systems by: (a) Demonstrating the feasibility and advantages of cell-free systems through use-inspired applications with specific emphasis on applications beyond human therapeutics; (b) Creating infrastructure components, such as tools, protocols, kits, datasets, and characterization services that can readily be accessed by third parties; and (c) Investing in workforce components focused on the training of translational talent with the skills and passion to engage in use-driven cell-free applications. CFIRE will use the Ideas Lab process (see PAPPG Chapter II.F.6), starting with an intensive meeting that brings together multiple diverse perspectives. The primary objectives of this Ideas Lab workshop will be to: identify specific opportunities to significantly reduce the cost of cell-free systems; establish acceptable standards for the fidelity and reproducibility; expand the range of capabilities in order to facilitate broader adoption of the technology; and identify and prioritize use-driven applications beyond human therapeutics.

This funding opportunity supports independent researchers in studying the prevention, diagnosis, and treatment of diseases related to military toxic exposures, benefiting Service Members, Veterans, and their families.

The Equitable and Affordable Solutions to Electrification (EAS-E) Home Electrification Prize offers up to $2.4 million in prizes for innovative solutions that advance the electrification retrofits of residential homes across all building types and geographies. The goal is to make electrification more affordable and accessible in existing U.S. homes, with a focus on equitable solutions for all homeowners, including those in low-income and under-resourced communities. The prize supports design solutions, tools, and technology innovations that enable the switch to electric products and reduce carbon emissions. Low-power electrification solutions are strongly encouraged. The competition consists of two phases: Phase 1 focuses on presenting proposed solutions and up to five winners receive a $5,000 cash prize and a $75,000 voucher to work with DOE national laboratories. Phase 2 involves finalizing teams, demonstrating functional prototype solutions, and up to three winners receive prizes, with a top prize of $1 million. The competition is open to individuals, private entities, nonfederal government entities, and academic institutions. For more information, refer to the official rules document.

This funding opportunity provides financial support to organizations that create and manage equine therapy programs aimed at improving the well-being and quality of life for disabled veterans and members of the Armed Forces.

The National Cancer Institute (NCI) intends to publish a Notice of Funding Opportunity (NOFO) to solicit applications for the RNA Modifications Driving Oncogenesis (RNAMoDO) Initiative. It aims to promote mechanistic research in the emerging area of RNA modifications that drive oncogenesis, with a focus on the central role of RNA modifications in translational reprogramming of cancer cells. RNA modifications have been recognized to exert a substantial impact on gene expression and function and their de-regulation has been linked to the cancer phenotype. In particular, recent insights point to a crucial role for mRNA, tRNA, and rRNA modifications in translational reprogramming during tumor initiation, progression, and adaptation to therapy. However, the molecular mechanisms underlying this reshaping of the translatome caused by dynamic changes in RNA modifications, and especially the interplay between different RNA modifications within and across RNA molecules during translation, are not understood and represent the focus of this initiative. Historically, the research community has largely pursued investigations of RNA modifications by studying single RNA species and modification types. However, elucidating how dysregulation of mRNA, tRNA, and rRNA modifications reprograms translation to drive oncogenesis is not likely feasible for any single research laboratory, but will require the combination of expertise in mRNA, tRNA and rRNA biology, translational regulation, and cancer research. To stimulate progress in this emerging field, the RNAMoDO program will support collaborative research projects, preferably using an MPI structure, on how modifications in mRNA, tRNA, and rRNA molecules can drive the oncogenic process through translational reprogramming. To be responsive to the NOFO, each project will also explore the impact of interactions between modifications residing on the same or different RNA molecules during translation. This Notice of Intent to Publish (NOITP) is being provided to allow potential applicants sufficient time to develop meaningful collaborations and responsive projects. The NOFO is expected to be published in the early Fall of 2024, with an expected application due date in November 2024. The NOFO will utilize the U01 mechanism for Research Project Cooperative Agreement (Clinical Trial Not Allowed). Potential applicants are encouraged to view the presentation of this initiative to the NCI Board of Scientific Advisors (BSA), available at: (https://videocast.nih.gov/watch=54423) beginning at 1 hour, 32 minutes, 52 seconds. Presentation slides are downloadable at https://deainfo.nci.nih.gov/advisory/bsa/0324/Maas.pdf.

The U.S. Department of State, Bureau of Democracy, Human Rights, and Labor (DRL) announces an open competition for a new project, Dignity in Documentation Initiative (DIDI). This effort focuses on global, integrated, and holistic CRSV documentation programming seeking truth and justice for victims and survivors as well as accountability for crimes committed in violation of international human rights and humanitarian law. The DIDI must take a survivor-centered and trauma-informed approach, prioritizing the individual needs and efforts of CRSV survivors, while supporting survivor networks, civil society, and community-based organizations. This solicitation will result in the first tranche of these program efforts, with incremental funding envisioned over the life of the 5-year project, depending on the availability of funding.

The key aspects of this award are: Impact: The SRA is intended to support research designed to have a major impact on the health and well-being of melanoma survivors, their families, and/or caregivers. Impactful research will accelerate the movement of promising ideas into clinical applications or other real-world applications and advance the field of melanoma-specific quality of life and survivorship. Study Design: Applications should clearly articulate and justify the chosen study design. Studies proposing retrospective analyses or prospective enrollment should clearly describe the architecture of the study (e.g., descriptive, correlational, field experimental, meta-analyses) and the study population(s). The study population(s) should be representative of the people who are anticipated to benefit from the research. If applicable, questionnaires should be described in sufficient detail to justify interpretation of potential results. Melanoma Consumer Collaboration: For the purposes of the SRA, a melanoma consumer is defined as a melanoma survivor, family member, and/or caregiver who can provide lived experience expertise to the research project team. Applicants to the SRA are required to establish a collaborative research approach with the melanoma consumer community to maximize the impact and translatability of the research for the benefit of the intended melanoma community(ies). The research team must include at least one melanoma consumer or a melanoma-community supporting organization who will be integral to the planning, execution, and implementation of the proposed research. The role of the melanoma consumer collaborator(s) should include providing objective input on the research question being addressed; the study design, execution, and evaluation; and the potential impact of the research outcomes on the health and well-being of melanoma survivors, their families, and/or their caregivers. The melanoma consumer collaborator(s) should be active participants and integrated into the research team; their participation should not be limited only to passive activities (e.g., attending seminars or quarterly team meetings). Additional information and resources for establishing a collaborative research approach with the melanoma consumer community is provided below.Other Important Considerations:Collaborative Research Approaches: Collaborative research approaches create partnerships between scientific researchers and, for the purposes of the SRA, melanoma consumers to create knowledge useable by both sets of stakeholders. Recognizing the strengths of each partner, scientific researchers and melanoma consumers collaborate and contribute equitably on all aspects of the project, which may include needs assessment, planning, research intervention design, implementation, evaluation, and dissemination. Collaborative research approaches feature shared responsibility and ownership for the research project to ensure non-tokenistic involvement of the melanoma consumers within the research team. Research results are jointly interpreted, disseminated, and fed back to affected communities and in some instances may be translated into interventions or policy.Collaborative relationships with the melanoma consumer community may be established through integrating melanoma consumers and/or melanoma-community supporting organizations into research teams as co-researchers, advisors, and/or consultants. Examples for implementing collaborative research approaches are listed below, but each research team may pursue other options as appropriate for the proposed research: The research team includes at least one melanoma consumer who will provide advice and consultation throughout the planning and implementation of the research project. The consumer(s) should be able to speak to the needs of the melanoma consumer community, not just speak to their own personal experiences. The research team establishes partnerships with at least one community-supporting organization that provides advice and consultation throughout the planning and implementation of the research project. Community-supporting organizations may include advocacy groups or other formal organizational stakeholders that can speak to the needs of the melanoma consumer community. The research team assembles a melanoma consumer community advisory board. The advisory board may include melanoma consumers, a coalition of community-supporting organizations, or any combination thereof that provides advice and consultation throughout the planning and implementation of the overall program and/or individual research projects.

This funding opportunity supports the development of advanced bioelectronic bandages that can monitor and treat wounds in real-time, specifically targeting military medical care for combat personnel.

This funding opportunity provides up to $1.3 billion to support the development and demonstration of advanced carbon capture technologies for power generation and industrial sectors, targeting a wide range of eligible applicants including educational institutions, nonprofits, and businesses.

This award is to support community development and resilience with geospatial data and digital technology by engaging university-aged youth. The activities anticipated as part of this award will add valuable, free and openly accessible data to digital ecosystems of lower and middle income countries, which in turn can be used by USAID programs and humanitarian assistance activities. The award will specifically focus on youth training, geospatial data collection, and analysis to help communities address local development challenges. Activities will also engage marginalized populations to ensure representation of the diversity of partner country populations. USAID anticipates awarding one to three grants and/or cooperative agreements under this Addendum. Issuance of this Addendum does not constitute an award or commitment on the part of the U.S. Government to make an award, nor does it commit the U.S. Government to pay for costs incurred in the preparation and submission of a Concept Note or Application(s). The actual number of assistance awards is subject to the availability of funds, as well as the viability of eventual full Applications received.

This grant seeks innovative proposals from a wide range of organizations, including universities and small businesses, to develop advanced technologies that enhance national defense capabilities.

The "Individually Measured Phenotypes to Advance Computational Translation in Mental Health (IMPACT-MH)" grant aims to support research that develops new behavioral measures and data infrastructure to improve the diagnosis, prognosis, and treatment of mental disorders.

This notice announces the opportunity to apply for funding under the Delta Region Maternal Care Coordination Program (Delta MCC). The purpose of this program is to improve and increase access to care for pregnant women and new mothers during and after pregnancy. To support this purpose, the objectives for the Delta MCC are to: 1. Use care coordination strategies to enhance and expand access to perinatal services in the Delta Region through a strong, diverse network of entities that represent the spectrum of care during and after pregnancy; 2. Utilize evidence-based, promising practices and/or value-based care model(s) in the planning and delivery of perinatal services; 3. Identify barriers to providing maternal health care in the region and strategies for addressing such barriers; and 4. Develop and implement deliberate and sustainable strategies of care coordination into policies, procedures, staffing, services, and communication systems (including but not limited to billing for appropriate services and partnering private and public payers). Applicants are encouraged to consider innovative strategies to meet the needs of and support pregnant women and new mothers. Some examples of activities that can be provided include: Provide outreach and education to pregnant women and new mothers on healthy nutrition to reduce risk of hypertension Provide screening and referral of mental health issues such as depression and anxiety including HRSAs Maternal Mental Health Hotline (1-833-TLC-MAMA) Refer pregnant women and new mothers to online or local support groups Recruitment of doula and midwifery services, community health workers, and/or maternal fetal specialist services Support patient care through telehealth Support travel costs, as necessary, of maternal health specialist to travel to pregnant woman Provide education and social support for pregnant women through the development of centering pregnancy (group prenatal care) visits; Provide resources and education to support in-home hypertension management and blood pressure self-monitoring and reporting; Support mobile prenatal and postpartum care visits for pregnant women and new mothers; Utilize development dyad models (mother and infant) to support combined postpartum and infant checkup visits; Support childcare for pregnant women and new mothers during prenatal and postpartum care visits; Applicants are encouraged to consider innovative strategies. Applicants are encouraged to propose ways to achieve these goals through the establishment or continuation of collaborative networks/consortiums of providers and services who support pregnant women and new mothers through pregnancy and post-partum. The networks will focus on reducing risk factors for pregnant women during and after pregnancy through screening and referral to needed services and interventions. HRSA recommends your members consist of a broad array of organizations from both traditional and non-traditional health care entities. Network members may include cross-sector entities such as health care providers, key services for supporting infant and child health, quality program providers, and insurers. See Appendix B for examples of the types of network members. This program funding should be used to complement the work of other organizations and should not duplicate or supplant activities that are funded through other federal mechanisms. The Delta MCC is a four-year program with year one (September 30, 2024 September 29, 2025) a planning year and years two, three, and four (September 30, 2025 September 29, 2028) focused on program implementation. For more details, see Program Requirements and Expectations.

This grant provides funding to early-career researchers focused on melanoma to support their independent research and professional development while fostering collaboration within a network of experts.

This grant provides funding for research aimed at developing new therapies for amyotrophic lateral sclerosis (ALS), specifically targeting projects that have already shown promise in preclinical studies and emphasize the use of biomarkers for therapeutic development.

The MBRP TTDA is a product-driven award mechanism intended to provide support for the translation of promising preclinical findings into products for clinical application in resource-limited settings, particularly within the pre-hospital, or early, acute phase of care environments. Applications must address one or more of the critical gaps included in the FY24 MBRP TTDA Focus Areas. Products under development must address the needs of military Service Members, Veterans, their beneficiaries, and the American public.The product(s) to be developed may be a tangible item such as a medical device or pharmacologic agent (including, but not limited to, drugs or biologics). Knowledge products may be considered, provided that the knowledge is applicable to a technology or therapeutic under development. (A knowledge product is a non-materiel product that addresses an identified need in one or more of the FY24 MBRP TTDA Focus Areas. A knowledge product is based on current evidence, aims to transition clinical practice standards, training, or tools into clinical practice, or supports materiel solutions [systems to develop, acquire, provide, and sustain medical solutions and capabilities], and educates or impacts behavior throughout the continuum of care, including primary prevention of negative outcomes.)At the time of pre-application submission the proposed product must have achieved a minimum technology readiness level (TRL) or knowledge readiness level (KRL) of 3 (Appendix II).Proof-of-concept AND a prototype/preliminary version of the proposed product demonstrating its potential utility must be established at the time of pre-application submission. Applications must include relevant data that support the rationale for the proposed study. These data may be unpublished and/or from the published literature.This award mechanism is intended to facilitate progression of research that is supported by significant preliminary data but has not yet advanced to the level of clinical use. Examples of the types of research that may be supported include, but are not limited to: Testing new therapeutic or technologic modalities (e.g., agents, delivery systems, chemical modification of lead compounds, device testing and/or validation) using established or validated preclinical systems Designing pilot or full-scale Good Manufacturing Practice (GMP) production of therapeutics and/or technologies for use in advanced preclinical studies Developing pharmacologic agents through absorption, distribution, metabolism, excretion, and toxicity studies Investigational New Drug- or Investigational Device Exemption-enabling studiesClinical trials and clinical research studies ARE NOT PERMITTED under this award mechanism. Projects involving limited use of commercially available human cells or anatomical specimens are permitted, provided that the use of such specimens is necessary for device or product development. Applicants interested in proposing clinical research should consider submitting to the FY24 MBRP Patient-Centered Research Award mechanism (HT942524MBRPPCRA).A clinical trial is defined in the Code of Federal Regulations, Title 45, Part 46.102 (45 CFR 46.102) as a research study in which one or more human subjects are prospectively assigned to one or more interventions (which may include a placebo or another control) to evaluate the effects of the interventions on biomedical or behavioral health-related outcomes.Studies that do not seek to measure safety, effectiveness, and/or efficacy outcome(s) of an intervention are not considered clinical trials.For the purposes of this funding opportunity, research that meets the definition of a clinical trial is distinct from clinical research. Clinical research encompasses research with human data, human specimens, and/or interaction with human subjects. Clinical research is observational in nature and includes:(1) Research conducted with human subjects and/or material of human origin such as data, specimens, and cognitive phenomena for which an investigator (or co-investigator) does not seek to assess the safety, effectiveness, and/or efficacy outcomes of an intervention. Research meeting this definition may include but is not limited to: (a) mechanisms of human disease, (b) diagnostic or detection studies (e.g., biomarker or imaging), (c) health disparity studies, and (d) development of new technologies.(2) Epidemiologic and behavioral studies that do not seek to assess the safety, effectiveness, and/or efficacy outcomes of an intervention.(3) Outcomes research and health services research that do not fit under the definition of clinical trial.Excluded from the definition of clinical research are in vitro studies that utilize human data or specimens that cannot be linked to a living individual and meet the requirements for exemption under 46.104(d)(4) of the Common Rule.Impact: The overall impact of the proposed research is a key component of this award mechanism. High-impact research will, if successful, lead to the development and translation of therapeutic or technologic advances for clinical application in the care of burn-injured casualties, such as detection, diagnosis, treatment, or burn complication prevention.Relevance to Military Health: Relevance to the health care needs of burn-injured military Service Members is a key feature of this award.Use of DOD or Department of Veterans Affairs (VA) Resources: Applications involving multidisciplinary collaborations among academia, industry, the military Services, the VA, and other federal government agencies are highly encouraged. These relationships can leverage knowledge, infrastructure, and access to unique clinical populations that the collaborators bring to the research effort, ultimately advancing research that is of significance to Service Members, Veterans, and/or their Families. If the proposed research relies on access to unique resources or databases, the application must describe the access at the time of submission and include a plan for maintaining access as needed throughout the proposed research. Applicants are encouraged to integrate and/or align their research projects with DOD and/or VA research laboratories and programs. Collaboration with DOD or VA investigators is also encouraged. A list of websites that may be useful in identifying additional information about ongoing DOD and VA areas of research interest or potential opportunities for collaboration can be found in Appendix IV.Rigor of Experimental Design: All projects should adhere to a core set of standards for rigorous study design and reporting to maximize the reproducibility and translational potential of preclinical research. The standards are described in SC Landis et al., 2012, A call for transparent reporting to optimize the predictive value of preclinical research, Nature 490:187-191 (www.nature.com/nature/journal/v490/n7419/full/nature11556.html). While these standards are written for preclinical studies, the basic principles of randomization, blinding, sample-size estimation, and data handling derive from well-established best practices in clinical studies. Projects that include research on animal models are required to submit Attachment 8, Animal Research Plan, as part of the application package to describe how these standards will be addressed. Applicants should consult the ARRIVE guidelines 2.0 (Animal Research: Reporting In Vivo Experiments) to ensure relevant aspects of rigorous animal research are adequately planned for and, ultimately, reported. The ARRIVE guidelines 2.0 can be found at https://arriveguidelines.org/arrive-guidelines.The CDMRP expects to allot approximately $4.4M to fund approximately two MBRP Technology/Therapeutic Development Award applications. Funding of applications received is contingent upon the availability of federal funds for this program as well as the number of applications received, the quality and merit of the applications as evaluated by scientific and programmatic review, and the requirements of the government. Funds to be obligated on any award resulting from this funding opportunity will be available for use for a limited time period based on the fiscal year of the funds. It is anticipated that awards made from this FY24 funding opportunity will be funded with FY24 funds, which will expire for use on September 30, 2030.The funding instrument for awards made under the program announcement will be assistance agreements, contracts, or Other Transactions. The type of instrument used to reflect the business relationship between the organization and the government is at the discretion of the government, in accordance with the Federal Grant and Cooperative Agreement Act of 1977, as amended, 31 USC 6301-6308, which provides the legal criteria to select a procurement contract or an assistance agreement. The USAMRDC will also consider the use of Other Transactions (OTs) as a vehicle for award, in accordance with the conditions in 10 USC 4021 and 10 USC 4022.An assistance agreement can take the form of a grant or cooperative agreement. The level of government involvement during the projects period of performance is the key factor in determining whether to award a grant or cooperative agreement. If no substantial government involvement is anticipated, a grant will be made (31 USC 6304). Conversely, if substantial government involvement is anticipated, a cooperative agreement will be made (31 USC 6305). Substantial involvement means that members of the U.S. government will assist, guide, coordinate, or participate in project activities.A contract is required when the principal purpose of the instrument is to acquire property or services for the direct benefit or use of the U.S. government.An Other Transaction will also be considered as a vehicle for award under this BAA, in accordance with 10 USC 4021 and 10 USC 4022. The OT authorities were created to give DOD the flexibility necessary to adopt and incorporate business practices that reflect commercial industry standards and best practices into its award instruments. When leveraged appropriately, OTs provide the government with access to state-of-the-art technology solutions from traditional and non-traditional defense contractors (NDCs), through a multitude of potential teaming arrangements tailored to the particular project and the needs of the participants. OTs can help to foster new relationships and practices involving traditional and NDCs, especially those that may not be interested in entering into FAR-based contracts with the government; broaden the industrial base available to government; support dual-use projects; encourage flexible, quicker, and cheaper project design and execution; leverage commercial industry investment in technology development and partner with industry to ensure DOD requirements are incorporated into future technologies and products; and collaborate in innovative arrangements. OTs are not FAR-based procurement contracts, grants, cooperative agreements, or cooperative research and development agreements.The award type, along with the start date, will be determined during the negotiation process.The anticipated total costs budgeted for the entire period of performance for an FY24 MBRP Technology/Therapeutic Development Award should not exceed $2.2M. Refer to Section II.D.6, Funding Restrictions, for detailed funding information.Awards supported with FY24 funds will be made no later than September 30, 2025. For additional information refer to Section II.F.1, Federal Award Notices.

The National Institute on Aging is offering a grant for graduate students interested in aging-related research, providing funding and support for their doctoral dissertation projects and transition into postdoctoral positions in the field.

This funding opportunity provides financial support for faculty and students at under-resourced academic institutions to collaborate with NASA on research projects, fostering mentorship and skill development in STEM fields.